Ependymoma Drug Market
- 2026 年市場規模
- USD 172.3 Mn
- 2033 年預估規模
- USD 239.4 Mn
- 年複合成長率 CAGR
- 4.8%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Ependymoma Drug Market, By Drug Type (Corticosteroids, Antiseizure Agents, Others), By Disease Type (Subependymoma, Myxopapillary Ependymoma, Anaplastic Ependymoma, Classic Ependymomas), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Ependymoma is a rare type of brain tumour called a glioma. It starts from ependymal cells in the brain or spinal cord. Ependymomas can develop in children and adults. They are soft, grayish, or red tumors which may contain cysts or mineral calcifications. Symptoms of ependymomas depend on whether the tumor is in the brain or the spinal cord. These tumors are divided into four major types, subependymoma, myxopapillary ependymoma, anaplastic ependymoma and classic ependymomas. Symptoms of an ependymoma are related to the location and size of the tumor. In infants, increased head size may be one of the first symptoms. Irritability, sleeplessness, and vomiting may develop as the tumor grows. In older children and adults, nausea, vomiting, and headache are the most common symptoms
Market Dynamics
Key players operating in the global ependymoma drug market are focusing on increasing research and development for ependymoma which is expected to drive the market growth during the forecast period. For instance, in April 2022, Pediatric Brain Tumor Consortium initiated Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma. The study is estimated to be completed in July 30, 2030. Moreover, increasing research funding for ependymoma is expected to propel growth of the global ependymoma drug market over the forecast period. For instance, in November 2021, a team of scientists led by researchers at the Yale School of Public Health had received a US $13 million grant to investigate the molecular evolution of lower grade gliomas, slow growing but malignant brain tumors that primarily affect young adults.
Key features of the study
• This report provides an in-depth analysis of the global ependymoma drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global ependymoma drug market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
• Key companies covered as a part of this study include Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global ependymoma drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ependymoma drug market
Market Segmentation
• Global Ependymoma Drug Market, By Drug Type
o Corticosteroids
o Antiseizure Agents
o Others
• Global Ependymoma Drug Market, By Disease Type
o Subependymoma
o Myxopapillary Ependymoma
o Anaplastic Ependymoma
o Classic Ependymomas
• Global Ependymoma Drug Market, By Distribution Channel
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• Global Ependymoma Drug Market, By Region
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East & Africa
GCC Countries
Israel
Rest of Middle East & Africa
• Key Players
o Fera Pharmaceuticals
o Pfizer
o Novartis AG
o Merck KGaA
o Baxter
o Cipla Limited
o Zydus Cadila
o Lupin Pharmaceuticals, Inc.
o UCB, Inc.
o APOTEX INC
o Moleculin Biotech, Inc.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Type
Market Snapshot, By Disease Type
Market Snapshot, By Distribution Channels
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Opportunity
o Impact Analysis
o Regulatory Scenario
o Market Trends
o Key Developments
o Epidemiology
o PEST Analysis
o Collaboration and Acquisition
o Porters Analysis
o Pipeline Analysis
4. Global Ependymoma Drug Market, By Drug Type, 2026-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2030 (%)
Y-o-Y Growth Analysis, 2022 – 2030
Segment Trends
o Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
o Antiseizure Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
5. Global Ependymoma Drug Market, By Disease Type, 2026-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2030 (%)
Y-o-Y Growth Analysis, 2022 – 2030
Segment Trends
o Subependymoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
o Myxopapillary Ependymoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
o Anaplastic Ependymoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
o Classic Ependymomas
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
6. Global Ependymoma Drug Market, By Distribution Channel, 2026-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2030 (%)
Y-o-Y Growth Analysis, 2022 – 2030
Segment Trends
o Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
o Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
o Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033 (USD Mn)
7. Global Ependymoma Drug Market, By Region, 2026-2033 (USD Mn)
o Introduction
Market Share Analysis, By Region, 2026 and 2030 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2030
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Countries, 2026-2033 (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026-2033 (USD Mn)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Fera Pharmaceuticals
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Pfizer
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Merck KGaA,
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Baxter
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Cipla Limited
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Zydus Cadila
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Lupin Pharmaceuticals, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
UCB, Inc.
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
APOTEX INC
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
Moleculin Biotech, Inc.,
o Company Highlights
o Product Portfolio
o Key Highlights
o Financial Performance
o Strategies
9. Section
o Research Methodology
o About us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們